Authors
Earlier this month, Turquoise Health submitted a public comment in response to CMS-0042-NC, a Request for Information (RFI) focused on the health technology ecosystem.
We focused our feedback on two specific sections of the RFI:
- PC-12; regarding binding cost estimates for pre-defined periods as valuable operational health data use cases for patients and caregivers
- TD-19; regarding price transparency implementation
Turquoise is in full support of CMS’ commitment to using price transparency data and innovative frameworks to create binding upfront cost estimates. The Turquoise site has thousands of patients engaging with our data, and each of those site visits points to the need for clarity and transparency in understanding the cost of care.
Our full comment can be summarized as follows:
- We emphasize the importance of enforcement dates for AEOBs and GFEs as the primary mechanism for for binding cost estimates
- We offer an open-source framework as an innovative solution for creating service packages to fulfill the No Surprises Act requirements and allow patients to understand their cost of care up front
- We summarize the highest-impact workflow improvements and benefits from price transparency
- We offer practical paths to motivate solution development
Related resources
Learn, listen, and watch the latest on price transparency.

Transparency in Coverage Final Rule (2026): What Changes for Payer Machine-Readable Files
Payers will report by network instead of plan, move from monthly to quarterly, and attest to their data. We expect files to be slimmed down, more organized, and easier to find online.

Prescription Drugs Rates Get A Mandated Due Date with Dec 2027 Enforcement
What this means for manufacturers ability to provide patients a personalized OOP cost for drugs

Transparency in Coverage Update Trims Down Payer MRFs & Brings Back the Rx File
CMS's first major TiC overhaul since 2022 simplifies payer files and sets a December 2027 enforcement date for the prescription drug file. Here's what it means for patients and the industry


